Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
Clinical trial NCT03267654 · UNKNOWN
Trial details
- NCT number
- NCT03267654
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-12
- Primary completion
- 2020-10-20
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.